Javascript must be enabled to continue!
CD40-CD40 ligand
View through CrossRef
Abstract
CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family, and that was first identified and functionally characterized on B lymphocytes. Its critical role in T cell-dependent humoral immune responses was demonstrated by patients with the hyper-IgM syndrome, as well as by gene targeting in mice. However, in recent years it has become clear that CD40 is expressed much more broadly, including expression on monocytes, dendritic cells, endothelial cells, and epithelial cells. In addition, the CD40-ligand (CD40-L/CD154), a member of the TNF family, is also expressed more widely than activated CD4+ T cells only. Therefore it is now thought that CD40-CD40-L interactions play a more general role in immune regulation. Collectively these studies have culminated in pre-clinical and clinical studies that are in progress. This article reviews recent developments in this field of research, with main emphasis on (1) structure and expression of CD40 and its ligand; (2) CD40 signal transduction; (3) in vitro function of CD40 on different cell types; and (4) in vivo functions of CD40/CD40-L interactions. J. Leukoc. Biol. 67: 2–17; 2000.
Title: CD40-CD40 ligand
Description:
Abstract
CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family, and that was first identified and functionally characterized on B lymphocytes.
Its critical role in T cell-dependent humoral immune responses was demonstrated by patients with the hyper-IgM syndrome, as well as by gene targeting in mice.
However, in recent years it has become clear that CD40 is expressed much more broadly, including expression on monocytes, dendritic cells, endothelial cells, and epithelial cells.
In addition, the CD40-ligand (CD40-L/CD154), a member of the TNF family, is also expressed more widely than activated CD4+ T cells only.
Therefore it is now thought that CD40-CD40-L interactions play a more general role in immune regulation.
Collectively these studies have culminated in pre-clinical and clinical studies that are in progress.
This article reviews recent developments in this field of research, with main emphasis on (1) structure and expression of CD40 and its ligand; (2) CD40 signal transduction; (3) in vitro function of CD40 on different cell types; and (4) in vivo functions of CD40/CD40-L interactions.
J.
Leukoc.
Biol.
67: 2–17; 2000.
Related Results
Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Abstract
During experimental lung metastasis, procoagulant tumor cells adhere to the microvascular endothelium and activate coagulation, which leads to thrombin gene...
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract
Background: Currently bispecific monoclonal antibodies gain traction in pharmacology as a way to simultaneously target different surface molecules on immune...
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
Abstract
CD40 is a membrane differentiation antigen constitutively expressed on B cells that induces B cell growth and Ig synthesis after ligation with anti-CD40 ...
Agonistic CD40 Antibodies in Cancer Treatment
Agonistic CD40 Antibodies in Cancer Treatment
CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presenta...
Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy
Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy
Abstract
CD40 agonistic antibody is emerging as a front-line immunotherapy for patients with cancer. However, despite its remarkable curative effects, serious immune...
Abstract 501: Nuclear Factor-κB Is Involved in Platelet CD40 Signaling and Activation
Abstract 501: Nuclear Factor-κB Is Involved in Platelet CD40 Signaling and Activation
Introduction and hypothesis:
CD40 ligand (CD40L) is a thrombo-inflammatory molecule that predicts cardiovascular events. Platelets constitute the major source of solubl...
miRNA-145 inhibits VSMC proliferation by targeting CD40
miRNA-145 inhibits VSMC proliferation by targeting CD40
AbstractRecent studies have demonstrated functions of miR-145 in vascular smooth muscle cells (VSMCs) phenotypes and vascular diseases. In this study, we aim to determine whether C...
Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Abstract
Abstract 3607
Background:
In B-cell chronic lymphocytic leukemia (B-CLL) there is a well documented intr...

